A prospective randomised placebo controlled trial of treatment for fibrosing alveolitis in scleroderma

Completed

• Conditions: Fibrosing alveolitis in scleroderma; Musculoskeletal Diseases; Systemic sclerosis

• Registration Number: ISRCTN91217042
• Lead Sponsor: Arthritis Research Campaign (ARC) (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2002-07-15
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

1. Aged 18 - 75 years
2. American College of Rheumatology (ACR) criteria for scleroderma
3. Evidence for fibrosing alveolitis - High Resolution Computed Tomography (HRCT) or surgical biopsy

Exclusion Criteria

Not provided at time of registration

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Change in percent predicted Forced Vital Capacity (FVC)<br>2. Change in single-breath diffusing capacity for carbon monoxide (DLCO)

Secondary Outcome Measures

Name	Time	Method
1. Changes in appearance on high-resolution computed tomography<br>2. Change in dyspnoea scores